BiotechTube

CT-P41 + US-licensed Prolia

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Postmenopausal Women With Osteoporosis

Conditions

Postmenopausal Women With Osteoporosis

Trial Timeline

Jun 17, 2021 → Nov 16, 2023

NCT ID
NCT04757376

About CT-P41 + US-licensed Prolia

CT-P41 + US-licensed Prolia is a phase 3 stage product being developed by Celltrion for Postmenopausal Women With Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT04757376. Target conditions include Postmenopausal Women With Osteoporosis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT06037395Phase 1Completed
NCT04757376Phase 3Completed

Competing Products

20 competing products in Postmenopausal Women With Osteoporosis

See all competitors
ProductCompanyStageHype Score
ENZ215 + ProliaAlkem LaboratoriesPhase 3
77
teriparatide + teriparatide + Placebo + Calcium Supplement + Vitamin D SupplementEli LillyPhase 3
77
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
LetrozoleChugai PharmaceuticalPhase 2
52
Eldecalcitol soft capsulesChugai PharmaceuticalPre-clinical
23
LetrozoleChugai PharmaceuticalPhase 2
52
LetrozoleChugai PharmaceuticalPhase 2
52
menatetranone + alfacalcidolEisaiPhase 3
77
teriparatide + raloxifene + placeboEli LillyPhase 3
77
Teriparatide + Strontium ranelateEli LillyApproved
85
teriparatideEli LillyApproved
85
LY333334 + PlaceboEli LillyPhase 1
33
Teriparatide + RaloxifeneEli LillyApproved
85
teriparatide + aldrenodate + raloxifeneEli LillyApproved
85
LAE102 SC + Placebo SC + LAE102 IV + Placebo IVEli LillyPhase 1
33
BlosozumabEli LillyPhase 1
33
BlosozumabEli LillyPhase 1
33
Arzoxifene + RaloxifeneEli LillyPhase 3
77
teriparatide + raloxifene HCl + placeboEli LillyApproved
85
Raloxifene HCL + Raloxifene HCL + PlaceboEli LillyPhase 3
77

Other Products from Celltrion

Azathioprine + PlaceboApproved
85
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)Approved
85
Infliximab + Infliximab + InfliximabApproved
85
Pioglitazone + Alogliptin + Alogliptin + Metformin + DapagliflozinApproved
85
Pioglitazone 15 MG [Actos] + Empagliflozin 10 MG [Jardiance] + Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]Approved
85